A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries a risk of bleeding and infection. Findings from this research may offer a more accurate and reliable method to diagnose prostate cancer.
“This study is exciting because it has the potential to offer a non-invasive alternative to the traditional PSA test in order to diagnose significant prostate cancers,” said Craig Rogers, M.D., chair of the Vattikuti Urology Institute at Henry Ford Health System. “The discovery of new biomarkers ultimately benefits our patients, as it advances our understanding of this complex disease and how to most effectively treat it.”
When the KLK4 protein coding gene and KLKP1 pseudogene fuse together, the fusion gene KLK4-KLKP1 is formed. Pseudogenes like KLKP1 are the non-functional, or dead, versions of an actual gene that is normally not expressed in a cell but can become active in cancerous cells and disrupt the functions of the actual gene.
“The unique feature of this fusion gene is the conversion of the noncoding pseudogene KLKP1 into a protein coding gene, and its unique expression in about 30 percent of high Gleason grade prostate cancer,” said Dr. Palanisamy. “Like other ETS family gene fusions, KLK4-KLKP1 can also be detected in the urine samples of patients with prostate cancer, enabling non-invasive detection of prostate cancer. Given the unique feature of this fusion, prostate cancer specific expression, oncogenic properties and noninvasive detection, this novel gene fusion has the potential to be used as a biomarker for early detection of prostate cancer and a therapeutic target.”
The researchers conducting this study screened a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients of other races), which revealed that the KLK4-KLKP1 fusion gene is expressed in about 32 percent of prostate cancer patients, representing a distinct subset of prostate cancer cases. Correlative analysis showed that the new fusion gene can be used in combination with other prostate cancer molecular markers for cancer detection. In addition to urine samples, the fusion could also be detected in needle biopsy tissue samples by using a specific antibody.
Prostate cancer is the most common cancer among men in the United States. Advances in diagnosis, treatment, and management have resulted in increased survival rates, yet prostate cancer still remains the second leading cause of cancer-related deaths among American men. One of the major barriers to achieving successful prostate cancer control is the underlying molecular complexity of the disease itself.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- How AI can predict lethal prostate canceron January 16, 2021 at 1:37 am
An innovative new screening program is helping men across Australia monitor their health by predicting their risk of developing prostate cancer. Australian medical technology company Maxwell Plus is ...
- Prostate cancer warning: Bisphenol A found on receipts could be increasing your riskon January 15, 2021 at 8:01 pm
More and more cases of men being diagnosed with the deadly disease are taking place in the UK. Could a chemical in receipts be the cause of the sudden surge in recent years?
- Dr Luis Carrascosa on Innovations in Radiation Therapy for Prostate Canceron January 15, 2021 at 2:09 pm
Luis Carrascosa, MD, a radiation oncologist at the Florida Cancer Specialists Ocala Cancer Center, discusses new and upcoming trends in radiation therapy for prostate cancer.
- An unexpected, and novel, target for prostate cancer: Our biological clockon January 15, 2021 at 1:59 pm
Researchers find that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair.
- Circadian Rhythm Target Identified for Prostate Canceron January 15, 2021 at 12:00 pm
Laboratory studies by researchers at the Sidney Kimmel Cancer-Jefferson Health (SKCC) have found an unexpected role for the circadian clock gene CRY1, in prostate cancer progression. They say their ...
- How a gene linked to the circadian clock could point to new prostate cancer treatmentson January 15, 2021 at 6:54 am
Studies have shown that disruptions in circadian rhythms caused by chronic sleep deprivation and other lifestyle-related issues are linked to an increased incidence of some cancers, including prostate ...
- Artificial intelligence tool for reading MRI scans could transform prostate cancer surgery and treatmenton January 15, 2021 at 6:17 am
Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict ...
- Researchers discover unexpected role for the clock gene in prostate cancer progressionon January 15, 2021 at 4:57 am
Our biological or circadian clock synchronizes all our bodily processes to the natural rhythms of light and dark. It's no wonder then that disrupting the clock can wreak havoc on our body.
- Coffee consumption associated with lower risk of prostate canceron January 14, 2021 at 10:33 am
According to a recent meta-analysis of existing studies, males who drink coffee daily may have a lower risk of prostate cancer compared with those who do not.
- Higher coffee intake may be linked to lower prostate cancer riskon January 11, 2021 at 3:41 pm
Drinking several cups of coffee every day may be linked to a lower risk of developing prostate cancer, suggests a pooled data analysis of the available evidence, published in the online journal BMJ ...
via Bing News